Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
First dual coronavirus–norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro…
Month: August 2023
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platforms Capital resources…
Mersana Therapeutics Announces Second Quarter 2023 Financial Results
Organization fully focused on product candidates and collaborations based on next-generation ADC platforms Capital resources…
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
Recursion’s Pipeline Recursion’s internal pipeline as of Q2 2023 Deployed new digital chemistry technology, together…
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
Recursion’s Pipeline Recursion’s internal pipeline as of Q2 2023 Deployed new digital chemistry technology, together…
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 08,…
CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 08,…
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from…
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from…
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”)…
Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”)…
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating…
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating…
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense…
Cronos Group Reports 2023 Second Quarter Results
Industry-leading balance sheet with $841 million in cash and short-term investments Increased 2023 operating expense…
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral…